Analysts See $-0.26 EPS for Fate Therapeutics, Inc. (FATE)

July 14, 2018 - By Sonya McDaniel

Investors sentiment increased to 2.08 in 2018 Q1. Its up 0.50, from 1.58 in 2017Q4. It improved, as 9 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 23 funds opened positions while 31 raised stakes. 36.46 million shares or 12.96% more from 32.27 million shares in 2017Q4 were reported.
Quantbot Technologies Ltd Partnership stated it has 10,984 shares or 0.01% of all its holdings. State Street Corporation invested 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Renaissance Technology Ltd Limited Liability Company invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Moreover, Endurant Mngmt L P has 0.57% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 155,344 shares. Geode Cap Mngmt Llc owns 404,634 shares for 0% of their portfolio. Boston Advsrs Ltd Co accumulated 0.01% or 51,460 shares. Jpmorgan Chase Co holds 427,420 shares. Fmr Lc reported 0.01% stake. Atlantic Ltd Limited Liability Company reported 2,000 shares. Aqr Management Limited Com holds 32,037 shares or 0% of its portfolio. 683 Management Lc has 993,711 shares. Strs Ohio stated it has 11,100 shares. Acadian Asset Mngmt Ltd Com holds 10,347 shares or 0% of its portfolio. Neuberger Berman Gru reported 153,250 shares stake. Voya Inv Mgmt Ltd Liability Corporation holds 20,350 shares.

Analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $-0.26 EPS on August, 13.They anticipate $0.03 EPS change or 13.04 % from last quarter’s $-0.23 EPS. After having $-0.27 EPS previously, Fate Therapeutics, Inc.’s analysts see -3.70 % EPS growth. The stock decreased 0.50% or $0.06 during the last trading session, reaching $11.86. About 95,260 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 233.04% since July 14, 2017 and is uptrending. It has outperformed by 220.47% the S&P500.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Fate Therapeutics had 10 analyst reports since March 6, 2018 according to SRatingsIntel. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Thursday, March 15. Piper Jaffray has “Buy” rating and $20.0 target. The company was downgraded on Tuesday, March 6 by Raymond James. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Outperform” rating given on Tuesday, March 6 by Wedbush. BMO Capital Markets maintained the stock with “Outperform” rating in Tuesday, March 6 report. The firm earned “Buy” rating on Friday, April 6 by Wells Fargo. The firm earned “Hold” rating on Thursday, March 29 by H.C. Wainwright. The company was downgraded on Tuesday, March 6 by H.C. Wainwright. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Wednesday, May 16. Piper Jaffray has “Buy” rating and $2000 target. H.C. Wainwright maintained it with “Hold” rating and $12.0 target in Tuesday, March 20 report. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, March 6.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $626.90 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

More news for Fate Therapeutics, Inc. (NASDAQ:FATE) were recently published by:, which released: “Stem Cell Companies Innovating for the Future” on July 12, 2018.‘s article titled: “Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance” and published on June 20, 2018 is yet another important article.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.